Bisgram

Bisgram is an oral gastrointestinal medication developed by Ingram Biosciences, containing 120 mg of colloidal bismuth subcitrate as its active ingredient. It is primarily indicated for the treatment of peptic ulcer disease, including both gastric and duodenal ulcers, and gastritis associated with *Helicobacter pylori* infection. The drug operates through a non-specific mechanism of action by forming a protective chelate layer over the ulcer base, which shields the mucosa from gastric acid and pepsin. Additionally, it exerts direct bactericidal activity against *H. pylori* by disrupting bacterial cell walls and inhibiting essential enzymes. Bisgram is typically utilized as a component of multi-drug eradication regimens that include antibiotics and acid-reducing agents to facilitate ulcer healing and bacterial clearance.

Brand names

Bisgram

Other names

Colloidal Bismuth Subcitrate